Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans
Open accessThe DOI matches its Crossref record; 35 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glucagon-like peptide (GLP)-1 lowers postprandial glycemia primarily through inhibition of gastric emptying. We addressed whether the GLP-1–induced deceleration of gastric emptying is subject to rapid tachyphylaxis and if so, how this would alter postprandial glucose control. RESEARCH DESIGN AND METHODS: Nine healthy volunteers (25 ± 4 years old, BMI: 24.6 ± 4.7 kg/m2) were examined with intravenous infusion of GLP-1 (0.8 pmol · kg−1 . min−1) or placebo over 8.5 h. Two liquid mixed meals were administered at a 4-h interval. Gastric emptying was determined, and blood samples were drawn frequently. RESULTS: GLP-1 decelerated gastric emptying significantly more after the first meal compared with the second meal (P = 0.01). This was associated with reductions in pancreatic polypeptide levels (marker of vagal activation) after the first but not the second meal (P < 0.05). With GLP-1, glucose concentrations declined after the first meal but increased after the second meal (P < 0.05). The GLP-1–induced reductions in postprandial insulin and C-peptide levels were stronger during the first meal course (P < 0.05). Likewise, glucagon levels were lowered by GLP-1 after the first meal but increased after the second test meal (P < 0.05). CONCLUSIONS: The GLP-1–induced delay in gastric emptying is subject to rapid tachyphylaxis at the level of vagal nervous activation. As a consequence, postprandial glucose control by GLP-1 is attenuated after its chronic administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Furthermore, GLP-1 can slow down gastric emptying by activating the vagus nerve, a part of the autonomic nervous system crucial for regulating the activities of the gastrointestinal tract.268”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [268]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 can slow down gastric emptying through its effects on smooth muscles and the nervous system in the gastrointestinal tract.264,268”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [268]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data also suggest that there is tachyphylaxis with prolonged use of GLP‐1 RAs [29, 60]”
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The magnitude of effect on GE, unlike the effects on glycaemic control or appetite, is attenuated with prolonged GLP-1 exposure.[2][3][4]”
From The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists (2020) · cites this paper as [3]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Native GIP mimicking postprandial GIP blood levels and GIPRAs did not reveal any relevant effects on GE. 3,[13][14][15]”
From The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists (2020) · cites this paper as [3]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“Although the glucose-lowering effect of GLP-1 in the fasting state is primarily mediated by its glucose-dependent augmentation of insulin secretion and inhibition of glucagon release (4,5), the key mechanism driving the postprandial normalization of glycemia by GLP-1 is a marked deceleration of gastric emptying leadin…”
BackgroundSelf-citationGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919 · cited 1×
“determined in ethanol-extracted plasma as previously described (15,18), using antiserum 89 390 for the measurement of intact GLP-1 [7–36 amide] plus cleavage products.”
MethodSelf-citationNauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817 · cited 2×
“fusion rate was based on previous studies (5,14) and was selected to increase”
BackgroundMethodSelf-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“A deceleration of gastric emptying by GLP-1 has been demonstrated in patients with type 2 diabetes and healthy individuals (5,8,14).”
BackgroundSelf-citationMitrakou, A., Kelley, D., Mokan, M., Veneman, T., Pangburn, T., Reilly, J., & Gerich, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201023260104 · Cited by 595 · cited 1×
“This is in contrast with previous studies showing a significant decline in glucagon levels after intravenous or oral glucose ingestion (31,32).”
ResultEnhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Nauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506 · cited 3×
“Given the importance of GIP as a physiologic incretin hormone (15,34), this might theoretically impair postprandial insulin responses and thus worsen glucose control.”
BackgroundMethodSelf-citationWillms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Self-citation
Cited by
Items 301–391 of 391
Meguro, S., Kawai, T., Matsuhashi, T., Sano, M., Fukuda, K., Itoh, H., & Suzuki, Y. (2014) · International Journal of Endocrinology · doi:10.1155/2014/927317 · Cited by 4
Hirota, Y., Matsuda, T., Nakajima, S., Takabe, M., Hashimoto, N., Nakamura, T., Okada, Y., Sakaguchi, K., & Ogawa, W. (2018) · Endocrine · doi:10.1007/s12020-018-1808-9 · Cited by 4
Patient Evaluation and Surgical Staging
Capla, J. M., & Hanna, S. A. (2023) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2023.07.004 · Cited by 4
Nauck, M. A., & Meier, J. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch48 · Cited by 4
Self-citationDuggan, E. W., & Umpierrez, G. E. (2024) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001438 · Cited by 3
Posada, M. M., Schneck, K. B., Morse, B. L., Rougée, L. R. A., Tham, L. S., Rehmel, J., Thompson, B., Stamatis, S. D., Hall, S. D., & Dickinson, G. L. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70101 · Cited by 4
Syam Das, S., Veena, R. M., Aneesa, P. A., Parappilly, S. J., Mulakal, J. N., Baby Chakrapani, P. S., & Krishnakumar, I. M. (2025) · Medicine · doi:10.1097/md.0000000000044590 · Cited by 4
“[18,19] The most commonly cited methodology for managing side effects of GLP-1 drugs is individualized and gradual dose-escalation of the medication, and if the symptoms are persistent or severe, needs to stop.”
Song, J., Fang, K., 张运周, Zhang, R., Yin, C., & Gao, D. (2026) · Neurological Research · doi:10.1080/01616412.2026.2640121 · Cited by 3
Nauck, M. A., Gallwitz, B., & Seufert, J. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-104866 · Cited by 4
“Die nachlassende Wirkung auf die Magenentleerung beruht vermutlich auf einer Tachyphylaxie, die bei anhaltend hohen Konzentrationen von GLP-1 beobachtet werden kann [15].”
BackgroundSelf-citationGlucagon-like peptide-1 and impaired counterregulatory responses to hypoglycemia in type 1 diabetes
Rocha, G. R., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.99928 · Cited by 4
Hirsch, I. B., Schneider, D., King, A., Polonsky, W. H., Reid, T., Shubrook, J. H., Verderese, C. A., Wallace, J. I., & Riddle, M. C. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2763 · Cited by 3
Tang, C. C., Lim, J. K., Loo, L. S., Jung, H., Кониг, М., & Tham, L. S. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2373 · Cited by 4
“In addition, Nauck et al 13 attributed this phenomenon to possible chronic exposure to GLP-1 leading to downregulation or desensitization of the GLP-1 receptors or through vagal nervous system activation.”
BackgroundGlucagon‐like peptide‐1 receptor agonists in the perioperative period: to cease or not to cease?
Martis, W. R., Sachithanandan, N., Chiang, C. Y., & Riedel, B. (2023) · ANZ Journal of Surgery · doi:10.1111/ans.18804 · Cited by 3
“6 Consequently, there is clinical uncertainty regarding the optimal management of these agents in the perioperative period.”
Perioperative Considerations for Patients on GLP1 Agonists
VanderWielen, B. A., & Beam, W. B. (2024) · Advances in Anesthesia · doi:10.1016/j.aan.2024.07.002 · Cited by 3
Johansen, N. J., Dejgaard, T. F., Lund, A., Vilsbøll, T., Andersen, H. U., & Knop, F. K. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-021861 · Cited by 3
“The incretin hormone, glucagon-like peptide-1 (GLP-1), regulates glucose metabolism through GLP-1 receptor-induced pancreatic and extrapancreatic effects, for example, increased glucose-dependent insulin secretion, lowered postprandial glucagon secretion and reduced rate of gastric emptying.(16) Furthermore, GLP-1 pro…”
BackgroundDecrease in the efficacy of glucagon-like peptide-1 receptor agonists: what is the reason?
Кушнарьова, Н. М., Zinych, О. В., Korpachev, V. V., Ковальчук, А., Prybyla, О. В., & Shyshkan-Shyshova, К. О. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.8.2021.246799 · Cited by 3
Hyperglycemia in the focus of prevention of age-related skin changes
Shperling, N. V., Chaplygin, A. V., & Васильевна, Ч. Н. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-360 · Cited by 2
Impact of GLP-1 receptor agonists on gastrointestinal function and symptoms
Frazier, R., & Hasler, W. L. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2579117 · Cited by 4
“Some suggest tachyphylaxis to GLP-1RA therapy is more prominent with long-acting formulations likely from sustained receptor exposure rather than short-acting agents like exenatide which which exert briefer inhibitory actions by vagal pathways [41].”
Almohammad, A. A., Aldossari, S. K., Sukumbaji, Z. A., Faden, R. A., Almutairi, M. A., Al-Harbi, N. H., Al-Saaib, M. Y., Almarshedy, B., Alharabi, E., Alhazri, W. A., et al. (2025) · Cureus · doi:10.7759/cureus.95792 · Cited by 10
“Additionally, GLP-1 reduces gastric contractions through vagal nerve activation, contributing to delayed gastric emptying [66,67].”
Pennycuff, J. E., Cortes-Mejia, N., Hernandez, M., Owolabi, A., Soliz, J., & Cata, J. (2026) · Anesthesia and Analgesia · doi:10.1213/ane.0000000000007967 · Cited by 2
Rega, M., Petraglia, F. M., D’Ursi, L., Buonocore, M., Criscuolo, D., & Santoro, A. (2026) · Clinical bioenergetics · doi:10.3390/clinbioenerg2010005 · Cited by 2
Asada, K., Tsujimoto, Y., Hoshino, Y., Tomiki, M., Sekiguchi, K., Yamashiro, K., & Nishimura, R. (2026) · Internal Medicine · doi:10.2169/internalmedicine.7186-26 · Cited by 2
Méndez-Pino, L., Goldblatt, J., Godie, D., Ravi, S., Williams, K., Amcheslavsky, J., Guerra‐Londono, C. E., & Ravikant, N. T. (2026) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-026-03187-3 · Cited by 2
“15,16,25,26 Despite this pharmacologic pattern, we did not observe a signi fi cant association between the duration of GLP-1 RA use and the presence of RGC.”
Mansour, A., Mohajeri‐Tehrani, M. R., Qorbani, M., Ghamari, M., Larijani, B. A., & Hosseini, S. (2020) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831/a000463 · Cited by 2
GIP und GLP-1-Rezeptoragonismus in der Therapie des Typ 2 Diabetes mit Fokus auf Tirzepatid
Nauck, M. A., Blüher, M., Meyhöfer, S. M., Heitmann, E., & Görgens, S. W. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2102-2436 · Cited by 3
“Eine schnell auftretende Tachyphylaxie kann diesen Effekt zwar beeinflussen und die verlangsamte Magenentleerung abmil-dern, jedoch nicht verhindern [84].”
BackgroundSelf-citationAlghamdi, F. A., Alshegifi, H., Alhuthayli, R., Helal, T., Huwait, T. A., Alharbi, T., Akbar, A. F., Alshehri, W., & Alsheikh, S. (2024) · Cureus · doi:10.7759/cureus.74345 · Cited by 3
Li, J., Mohamed, B. A., Huang, S., & Peng, Y. G. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2494646 · Cited by 3
“This suggests that even long-acting GLP-1 RAs can notably affect gastric emptying 8,47 .”
Giordano, S. A., Salval, A., Summa, P. G. D., & Oranges, C. M. (2025) · Surgeries · doi:10.3390/surgeries6020042 · Cited by 4
Miyagi, M., Uchino, H., Kumashiro, N., Higa, M., Shin, K., Sasamoto, M., Kitazato, H., Tamaki, M., Matsuhisa, M., & Hirose, T. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0486-1 · Cited by 2
“However, when using GLP-1RAs, we must pay attention to tachyphylaxis [16].”
BackgroundLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01047-y · Cited by 2
Self-citationSen, S., Pai, S., & Harbell, M. W. (2025) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001522 · Cited by 1
Bobok, N., & Halushko, O. A. (2025) · Problems of ageing and longevity (Ukraine) · doi:10.71012/pro-ageing-2025-4-05 · Cited by 1
GLP1 receptor analogues and perioperative management considerations: A narrative review
Lima, A. V., & Lopo, M. V. (2026) · Revista Española de Anestesiología y Reanimación (English Edition) · doi:10.1016/j.redare.2026.501985 · Cited by 1
Anderson, B. J., Daele, D. J. V., Claussen, A. D., Tanenbaum, Z. G., & Owen, S. R. (2026) · Annals of Otology Rhinology & Laryngology · doi:10.1177/00034894261450724 · Cited by 1
“26 In addition, randomized studies have shown that perioperative GLP-1RA administration may partially ameliorate the degree of hyperglycemia and need for insulin in patients undergoing cardiac surgery.”
Abenavoli, L., Loricchio, A. G., Lopez, I., Morano, D., Ismaiel, A., Dumitrascu, D. L., & Luzza, F. (2026) · Medicina · doi:10.3390/medicina62050986 · Cited by 1
“Long-acting GLP-1 receptor agonists also delay gastric emptying and reduce gastric motility, although these effects tend to attenuate over time and are thought to play a secondary role in long-term weight and glycemic control [17].”
Hyung, B., Ye, X. Y., Chandrakumar, M., Lovshin, J. A., & Peacock, S. C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70955 · Cited by 2
Al‐Majmuei, A., Alatoom, M., Abdullahi, F., Marza, L., Murjan, N. A., Qasmi, R. A., Al-Rahbi, T., AlOmar, H., Alsherooqi, R., & Arekat, D. Z. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02671-7 · Cited by 1
Vaciamiento gástrico y Diabetes mellitus tipo 2
Cadavid, C. A. Q., Regino, W. O., & Vega, R. F. (2015) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v63n2.46195 · Cited by 2
“El efecto sobre el VG de los análogos de acción larga se aminora con rapidez probablemente por la taquifilaxia secundaria a una estimulación permanente del receptor (54).”
BackgroundIncretin for the continuing treatment of secondary failure to metformin in Type 2 diabetes
Gallwitz, B. (2013) · Diabetes Management · doi:10.2217/dmt.13.29 · Cited by 1
Takeuchi, M., Okamoto, M., & Watanabe, N. (2018) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-018-9777-7 · Cited by 1
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
Self-citationNarayanasamy, S., & Kalagara, H. K. P. (2024) · Indian Journal of Anaesthesia · doi:10.4103/ija.ija_609_24 · Cited by 2
“[22] Short-acting GLP-1 RAs primarily reduce postprandial hyperglycaemia by reducing gastric emptying due to intermittent receptor stimulation.”
BackgroundThe Importance of Postprandial Hyperglycemia Position Statement of the Danube Mco Experts
Barkai, L., Hâncu, N., Jermendy, G., Konstantinova, M., Lichiardopol, R., Moța, M., Tankova, T. I., Temelkova, N., & Winkler, G. (2015) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.1515/rjdnmd-2015-0011 · Cited by 1
Miura, H., Muramae, N., Mori, K., Otsui, K., & Sakaguchi, K. (2022) · Cureus · doi:10.7759/cureus.25889 · Cited by 2
Whitledge, J. D., Kennedy, J. M., Watson, C. J., Malley, C., Simone, K. E., & Neavyn, M. (2025) · Journal of Medical Toxicology · doi:10.1007/s13181-025-01075-8 · Cited by 1
Traitement du diabète de type 2 : l’exénatide, en alternative ou en association à l’insuline ?
Guerci, B., & Sauvanet, J.-P. (2013) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(13)70536-4
Give the Receptor a Brake: Slowing Gastric Emptying by
Tong, J. (2014)
Pharmacologic Approach to Type 2 Diabetes in Obese Patients
Litwak, L., Musso, C., & Fuentes, S. (2014) · Springer eBooks · doi:10.1007/978-3-319-13126-9_10
Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists
Min, S. H., & Cho, Y. M. (2015) · Journal of Korean Diabetes · doi:10.4093/jkd.2015.16.4.252
“따라서 단시간 작용제에 비하여 장 시간 작용제는 식후 혈당 감소효과가 적고 식후 인슐린 분 비는 증가한다[26].”
Glucose metabolism in the critically ill.
Deane, A. (2012) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · Cited by 1
Blundell, J. E., Axelsen, M. B., Brooks, A., Flint, A., Kvist, T., Bergan, E. Q., & Hjerpsted, J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(16)31220-7 · Cited by 1
Non‐Insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Jorsal, T., & Knop, F. K. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch32
The role of gut hormones on food intake and carbohydrate tolerance
Tharakan, G. (2016) · Spiral (Imperial College London) · doi:10.25560/41846
“likely to contribute to its anorectic effect(106), although it has been reported that this effect may be temporary due to tachyphylaxis(107).”
BackgroundCombined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
Ruyatkina, L. A., & Sorokin, M. (2016) · Diabetes Mellitus · doi:10.14341/7875
THE ROLE OF THE INTESTINAL MICROBIOTA IN THE MODULATION OF FOOD INTAKE AND BODY WEIGHTPreprint
Dalby, M. J. (2017) · Thesis Commons (OSF Preprints) · doi:10.31237/osf.io/rqz2p
GLP-1受容体作動薬「リラグルチド」の2型糖尿病患者に対する1年間使用成績
南部, 拓., 村上, 隆., 優樹, 松., 浩司, 松., 米光, 新., 武呂, 誠., & 尚吾, 隠. (2014) · 糖尿病 · doi:10.11213/tonyobyo.57.153
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Guo, Z., Yuting, W., & Sun, X. (2021) · Research Square · doi:10.21203/rs.3.rs-520283/v1
Gallwitz, B. (2013) · Der Diabetologe · doi:10.1007/s11428-012-1018-7
dos Reis, J. R. C., Furtado, P. P. O., Resende, L. D. S., & Reis, B. C. C. (2022) · Revista Eletrônica Acervo Médico · doi:10.25248/reamed.e10289.2022 · Cited by 6
The GLP-1RAs: From Evolution to Revolution
Mishra, N. (2022) · The Singapore Family Physician · doi:10.33591/sfp.48.3.u2
Effects of various weight-reducing drugs on eating behavior
Георгиевич, З. Г., Golikova, T. I., Matveev, G. A., & Babenko, A. Y. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-185
Non‐insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36
Spence, D. B., Austin, R. P., Carrol, C., Pierce, S., Richter, D. L., Chamberlain, R., & Schenck, R. C. (2024) · JBJS Journal of Orthopaedics for Physician Assistants · doi:10.2106/jbjs.jopa.24.00005 · Cited by 2
Toxicology profile of a novel GLP-1 receptor biased agonist-SAL0112 in nonhuman primates
Sun, J., Xiao, Y., Hu, X., Chen, S., Huang, J., Ren, Z., Luo, B., Jiang, R., Zhang, H., & Shen, X. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.117125
Alhamedi, N. M. (2025) · Journal of Clinical Medical Research · doi:10.46889/jcmr.2025.6104 · Cited by 1
“Notably, delayed gastric emptying associated with GLP-1 receptor agonists has been linked to nausea, with prolonged-acting agents exhibiting a potentially reduced impact on gastric motility, thereby decreasing nausea [3,21,23].”
Análogos del receptor GLP1 y consideraciones en el manejo perioperatorio: una revisión narrativa
Lima, A. V., & Lopo, M. V. (2025) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2025.501985
Abdulraheem, A., Abujaber, B. A., Ayers, L., Afzal, U., Qarkash, D., Altork, N. A., Zureikat, Q. A., Bashiri, K., Almhanni, G., Peppas, S., et al. (2026) · Clinical Endoscopy · doi:10.5946/ce.2025.137
“34 In contrast, long-acting agents may lead to receptor downregulation and reduced responsiveness.”
Tudosie, A. C., Marin, L.-M., Popa, S. G., & Golli, A. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083628 · Cited by 2
McGuane, C., Farhadhar, N., Sharieff, K. A., Petrosky, S. N., & Alabasi, K. (2026) · Cureus · doi:10.7759/cureus.109731 · Cited by 1
Ganakumar, V., Fernandez, C. J., & Pappachan, J. M. (2026) · World Journal of Diabetes · doi:10.4239/wjd.116477
Preoperative fasting guidelines: A narrative review
Meyer, M. D., Romero, C. S., & de Velde, M. V. (2026) · European Journal of Anaesthesiology Intensive Care · doi:10.1097/ea9.0000000000000120 · Cited by 1
Dost, B., Turunç, E., Narayanan, M. K., Koneti, K. K., Bugada, D., Karapınar, Y. E., & CASSAI, A. D. (2026) · Saudi Journal of Anaesthesia · doi:10.4103/sja.sja_91_26 · Cited by 1
Miličević, T., Cvitković, I., Volčanšek, Š., Katsiki, N., Mikhailidis, D. P., Patoulias, D., & Muzurović, E. M. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2706660
“One such challenge lies in maintaining the long-term effectiveness of incretin therapy, which can be compromised by tachyphylaxis, the development of anti-drug antibodies, and alterations in gut microbiome composition [106,107].”
Malbert, C., Delarue, J., & Guéant, J. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.07.004 · Cited by 1
Kurowski, M., Rekiel, K., Marcinkowska, A., Ratajczyk, O., Urbanowicz, P., Iwankiewicz, S., Grzelczak, W., & mierczak, Z. K. (2026) · Medical Journal of Cell Biology · doi:10.2478/acb-2026-0005
Choudhary, A. K., & Sahu, S. (2026) · Research Square · doi:10.21203/rs.3.rs-10780569/v1
Pulsatile liraglutide on a biased tirzepatide background: a hypothesis
Kopitović, I. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1922908
“3): Short-term gastric-emptying tachyphylaxis and receptor-traf fi cking observations do not establish a cause of long-term attenuation (13, 14).”
GLP-1 agonists before endoscopy: separating fact from fiction
Shah, T. (2026) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001195
Seo, J., Choi, S., Kim, N., Kim, H., & Lim, H.-S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1846164
“Based on the results of this analysis, the time at TC 50 for efpeglenatide may correspond to the point at which the drug-related GI inhibitory effect, namely delayed gastric emptying, is approaching a dynamic balance with the body’s physiological adaptation (Nauck et al., 2011).”
InfluentialŠantić, R., Kumrić, M., Kurir, T. T., Rušić, D., & Božić, J. (2026) · Molecules · doi:10.3390/molecules31193375
“Repeated exposure within the same day also produced rapid tachyphylaxis of the emptying response [127].”
Turk, N., Yandle, E., Yang, J., Esquivel, M. M., Azagury, D. E., Moradi, F., & McLaughlin, T. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag376
Liu, C., Wang, Y., Liu, J., Tian, P., Liu, J., Li, M., Zhang, Z., & Zhang, P. (2026) · Peptides · doi:10.1016/j.peptides.2026.171524
GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases
Koceva, E., & Moll, G. N. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179406
Gastrointestinal Symptom Events and Motility Alterations Associated With GLP ‐1 Receptor Agonists
Cisneros, J. Z., Lupianez‐Merly, C., Dilmaghani, S., Lennon, R. J., Then, S., Fiero, P., Blundo, R., Farrugia, G., Camilleri, M., & Grover, M. (2026) · Neurogastroenterology & Motility · doi:10.1111/nmo.70458
Pharmacological Mechanisms of Once-Weekly GLP-1 Receptor Agonists for Type 2 Diabetes Management
Ali, M. A., Das, S., Kumar, R. R., & Rabindra, K. (2026) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/26oct881
Zakeri, N., & Tolvanen, L. (2026) · Nutrients · doi:10.3390/nu18213524
Fakri, A., Sekkal, M., Ababou, M., Jidal, M., Halhoul, Y., & Bensghir, M. (2026) · MedPeer publisher · doi:10.70780/medpeer.000qgxj
Metadata
- Authors
- Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J.
- Affiliations
- Diabeteszentrum Bad Lauterberg (DE)
- Conservative Emergency Room, Klinikum Krefeld, Krefeld, Germany
- University of Copenhagen (DK)
- St. Josef-Hospital (DE)
- Corresponding author
- Nauck, Michael A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-04-23
- Volume
- 60
- Issue
- 5
- Pages
- 1561-1565
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3292331
- OpenAlex
- W2163229244
- Cited by
- 392
- References
- 37
- Citations by year
- 2026: 35 · 2025: 32 · 2024: 38 · 2023: 23 · 2022: 18 · 2021: 22 · 2020: 21 · 2019: 23 · 2018: 20 · 2017: 17 · 2016: 24 · 2015: 26 · 2014: 33 · 2013: 42 · 2012: 11
- FWCI
- 24.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, tachyphylaxis, gastric emptying, postprandial glucose control, vagal activation, pancreatic polypeptide, insulin secretion, glucagon, C-peptide, mixed meal
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Gastric Emptying, Glucagon, Humans, Male, Tachyphylaxis, Postprandial Period, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.